Ceramidases in Hematological Malignancies: Senseless or Neglected Target?

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 9, 2011-11 ,pp. : 830-843

Bentham Science Publishers

Access to resources Recommend Favorite

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma

By Mita M. M.   Poplin E.   Britten C. D.   Tap W. D.   Rubin E. H.   Scott B. B.   Berk L.   Rivera V. M.   Loewy J. W.   Dodion P.   Haluska F.   Sarantopoulos J.   Mita A.   Tolcher A.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1104-1111

Oxford University Press

Access to resources Recommend Favorite

The emerging role of mammalian target of rapamycin inhibitors in the treatment of sarcomas

By Vemulapalli Sushma  

Targeted Oncology, Vol. 6, Iss. 1, 2011-03 ,pp. : 29-39

Springer Publishing Company

Access to resources Recommend Favorite

The Role of Mammalian Target of Rapamycin (mTOR) Inhibitors in the Treatment of Solid Tumors

By  

Current Cancer Therapy Reviews, Vol. 4, Iss. 3, 2008-08 ,pp. : 227-234

Bentham Science Publishers

Access to resources Recommend Favorite

Expression of mammalian target of rapamycin in atherosclerotic plaques is decreased under diabetic conditions: A mechanism for rapamycin resistance

By              

Molecular Medicine Reports, Vol. 9, Iss. 6, 2014-01 ,pp. : 2388-2392

Spandidos Publications

Access to resources Recommend Favorite